Noticias
From Molecule to Platform: What the Abogen–Novartis Deal Means for mRNA Innovation
As mRNA therapeutics move into new disease areas, the next challenge is turning promising science into scalable, reproducible development process...
Phase 3 Victory for First Individualized mRNA Cancer Vaccine: What Solutions Are Needed for the New Era of mRNA Therapeutics?
On August 19, 2026, monumental news capable of entering the annals of oncology history arrived: Moderna and Merck jointly announced that the Phase ...
Cancer Cell (IF 44.5) | Tumor Cells Resist Immune Checkpoint Therapy via Macrophage Efferocytosis-Mediated Fatty Acid Recycling
Source: Liang Z, Long X, Wong PP, et al. Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid...
From Research to Regulatory Practice: Advancing NAT-Based Mycoplasma Testing for Biologics
Mycoplasma contamination remains one of the most persistent safety concerns throughout biologics manufacturing—from cell banking and viral vector ...
Fast, Accurate, and Reliable Molecular Diagnostic Solutions for Nipah Virus Surveillance
Urgent Alert: Nipah Virus Outbreak in India
A recent Nipah virus (NiV) outbreak in West Bengal, India has triggered emergency public health resp...
Exciting News! Yeasen’s GMP-Grade UltraAAV PEI Transfection Reagent Achieves FDA DMF Registration
Yeasen Biotechnology has officially received confirmation from the U.S. Food and Drug Administration (FDA): our UltraAAV PEI Transfection Reagent–G...
Synthesis of siRNA and the Role of T4 RNA Ligase 2
Small interfering RNA (siRNA) is a powerful tool in molecular biology, widely used for gene silencing through RNA interference (RNAi). These short,...
Yeasen Groundbreaking Milestone in High Temperature Bst DNA Polymerase Evolution for Eliminating False Positive Issues in LAMP Assays
Published in ACS Catalysis
Loop-mediated isothermal amplification (LAMP) is a powerful DNA amplification technique celebrated for its simplicity...
Avance tecnológico del ARNm: Yeasen Revela el secreto de baja toxicidad y alta traducción de los mutantes de la ARN polimerasa T7
Enzima diseñada reduce los efectos nocivos dsRNA, allanando el camino para terapias de ARNm más seguras Investigadores de Yeasen Biotecnología y...
Sistema integrado de eliminación de ácido nucleico para producir enzimas moleculares de ADN bajo ultra limpio
La contaminación de ácidos nucleicos ha sido durante mucho tiempo un obstáculo importante para el avance de las tecnologías de diagnóstico molecula...
¡Felicidades! ¡El CAR Universal Allogénico de Blood del Cord de Ucello, aprobado por US FDA Ind!
Ucello Biotechnology Co., Ltd., un socio estratégico clave de Biotecnología Yeasen, ha desarrollado de forma independiente una inyección universal ...
Compartir el informe de validación del kit ELISA de ARN doble cadena (dsRNA) para promover la estandarización de la detección de dsRNA.
¿Está buscando una forma confiable de detectar ARN de doble cadena residual durante la transcripción in vitro de ARNm? No busque más que el kit ELI...